Candel Therapeutics(CADL) - 2023 Q2 - Quarterly Report

In connection with the November 13, 2018 issuance of Series B preferred stock we issued warrants to the purchasers of the Series B preferred stock, to purchase up to 7,344,968 shares of our common stock with an exercise price of $6.81 per share. We also issued a warrant to the NC Incorporated Ohio Trust, an irrevocable trust funded by us, to purchase 162,740 shares of our common stock,$0.01 par value, at an exercise price of $1.46 per share, subject to adjustments as specified in the warrant agreement (the ...